T1	Participants 104 166	progressive, metastatic, castration-resistant prostate cancer.
T2	Participants 268 324	metastatic castration-resistant prostate cancer (mCRPC).
T3	Participants 346 407	Men with progressive mCRPC after docetaxel-based chemotherapy
T4	Participants 712 747	873 patients were randomly assigned
